Holen Sie sich die Stockscreener-App
16.71
5.09%
0.81
Handel nachbörslich:
16.59
-0.12
-0.72%
Schlusskurs vom Vortag:
$15.90
Offen:
$16.2
24-Stunden-Volumen:
77,950
Relative Volume:
0.47
Marktkapitalisierung:
$699.05M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.43%
1M Leistung:
+49.46%
6M Leistung:
+134.03%
1J Leistung:
+0.00%
1-Tages-Spanne:
$16.08
$16.95
1-Wochen-Bereich:
$13.99
$16.95
52-Wochen-Spanne:
$5.83
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Firmenname
Zenas Biopharma Inc
Sektor
Branche
Telefon
857-271-2954
Adresse
852 WINTER STREET, SUITE 250, WALTHAM
Vergleichen Sie ZBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
16.71 | 665.16M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Eingeleitet | Wedbush | Outperform |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
Buy Rating Affirmed for Zenas BioPharma: Promising Developments in Obexelimab Platform Drive Confidence - TipRanks
Zenas BioPharma Faces Legal and Financial Challenges Amid Securities Class Action Lawsuit - TipRanks
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewswire
Zenas BioPharma Reports Q2 2025 Financial Results - TipRanks
Forecasting Zenas BioPharma Inc. price range with options dataTen-Year Sector Performance and Summary Analysis - Newser
Zenas BioPharma Advances 3 Major Clinical Trials with $274M Cash Runway Through 2026 - Stock Titan
Zenas BioPharma’s Growth Potential: Key Trials and Strategic Positioning Drive Buy Rating - TipRanks
Heatmap analysis for Zenas BioPharma Inc. and competitorsFree Watchlist for Smart Swing Trading - Newser
Zenas BioPharma Inc.’s Price Action Aligns with Quant SignalsConsistent Gain Investment Strategies Emerge - beatles.ru
Viridian Therapeutics, Inc.\DE SEC 10-Q Report - TradingView
How many analysts rate Zenas BioPharma Inc. as a “Buy”Get daily expert analysis on top stocks - Jammu Links News
Is Zenas BioPharma Inc. a growth stock or a value stockTriple-digit wealth increases - Jammu Links News
Zenas BioPharma Inc. Stock Analysis and ForecastInvest confidently with data-driven strategies - Jammu Links News
When is Zenas BioPharma Inc. stock expected to show significant growthUnlock exclusive trading strategies for gains - Jammu Links News
Is Zenas BioPharma Inc. a good long term investmentMaximize gains with professional stock picks - Jammu Links News
What are Zenas BioPharma Inc. company’s key revenue driversFree Daily Trading Room Entry - Jammu Links News
What are the latest earnings results for Zenas BioPharma Inc.Tremendous growth potential - Jammu Links News
Does Zenas BioPharma Inc. stock perform well during market downturnsSuperior trading gains - Jammu Links News
Is Zenas BioPharma Inc. stock overvalued or undervaluedExplosive earnings growth - Jammu Links News
Is it the right time to buy Zenas BioPharma Inc. stockMaximize portfolio value with smart investment plans - Jammu Links News
How strong is Zenas BioPharma Inc. company’s balance sheetInvest in stocks with strong fundamentals - Jammu Links News
What is the risk reward ratio of investing in Zenas BioPharma Inc. stockOutstanding capital returns - Jammu Links News
3 Highly Shorted Stocks That Could Be The Next Wall Street Sensations - Barchart.com
What are the technical indicators suggesting about Zenas BioPharma Inc.Daily Trading Guidance With Low Risk - Jammu Links News
Why is Zenas BioPharma Inc. stock attracting strong analyst attentionEntry Signal Planner To Watch Now - Jammu Links News
What is Zenas BioPharma Inc. company’s growth strategyPost Market Target Finder For Every Investor - jammulinksnews.com
Zenas BioPharma Inc. Shows Support at Fibonacci LevelVolume Based Entry Signal Strategy - beatles.ru
What makes Zenas BioPharma Inc. stock price move sharplyConsistent Gain Investment Strategies Emerge - metal.it
Zenas BioPharma Inc. Breaks Losing Streak — Is the Trend ReversingTrade Setups With AI Powered Filters Published - metal.it
What does ZBIO's flat EPS in 2024 suggest for short-term traders? - AInvest
Can Traders Expect Breakout From Zenas BioPharma Inc. This WeekTriple Digit Return Stock Predictions Released - metal.it
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference - The Globe and Mail
Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS (NASDAQ:ZBIO) - Seeking Alpha
How does Zenas BioPharma Inc. generate profit in a changing economyUnlock powerful market trend analysis - Jammu Links News
Warm Autoimmune Hemolytic Anemia Market Expands Amid Increased - openPR.com
Key External Factors That Drive Zenas BioPharma Inc. Stock Price MovementsRisk Limited High Gain Trades - metal.it
Finanzdaten der Zenas Biopharma Inc-Aktie (ZBIO)
Es liegen keine Finanzdaten für Zenas Biopharma Inc (ZBIO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):